Market Place
Sourcing Support
BerGenBio Appoints Olav Hellebø as CEO
20 Nov 2024 //
PR NEWSWIRE
BerGenBio Q3 Results 2024
13 Nov 2024 //
PR NEWSWIRE
BerGenBio Announces Safety Data From Phase 1b In NSCLC Patients
07 Oct 2024 //
PR NEWSWIRE
BerGenBio Announces Phase 1b Safety Data for NSCLC Patients
07 Oct 2024 //
PR NEWSWIRE
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
21 Aug 2024 //
PR NEWSWIRE
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
20 Aug 2024 //
PR NEWSWIRE
BerGenBio Collaborates With Tempus To Accelerate STK11m NSCLC Development
20 Aug 2024 //
PR NEWSWIRE
BerGenBio Selects 2nd Dose For Phase 2a STK11m NSCLC Trial
29 Jul 2024 //
PR NEWSWIRE
BerGenBio Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
PR NEWSWIRE
BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC
06 Nov 2023 //
PR NEWSWIRE
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
31 Oct 2023 //
PR NEWSWIRE
Data on BerGenBio`s selective AXL inhibitor bemcentinib to be presented
16 Oct 2023 //
PR NEWSWIRE
BerGenBio ASA: Approval of prospectus for the preferential Rights Issue
26 May 2023 //
PR NEWSWIRE
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR
18 Apr 2023 //
PR NEWSWIRE
BerGenBio Announces First Patient Dosed in Ph1b/2a Trial Evaluating Bemcentinib
09 Mar 2023 //
PR NEWSWIRE
BerGenBio Reports Fourth Quarter 2022 Financial Results
16 Feb 2023 //
PR NEWSWIRE
BerGenBio Announces Positive Data From Phase 2 of Bemcentinib with Pembrolizumab
15 Feb 2023 //
PR NEWSWIRE
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board
02 Feb 2023 //
PR NEWSWIRE
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS
25 Oct 2022 //
PRNEWSWIRE
BerGenBio randomises first patient in Covid-19 treatment study
28 Sep 2022 //
CLINICALTRIALSARENA
BerGenBio reports second quarter and half year 2022 financial results
22 Aug 2022 //
PRNEWSWIRE
BerGenBio announces ACCORD2 phase II study of bemcentinib in combo with SoC
26 Apr 2022 //
PHARMABIZ
BerGenBio, Oslo University`s Bemcentinib will be Studied in EU-SolidAct trial
27 Jan 2022 //
PRNEWSWIRE
BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11 (NSCLC)
09 Nov 2021 //
PRNEWSWIRE
Bergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11
09 Nov 2021 //
PRNEWSWIRE
BerGenBio Presents Encouraging Combined Data for Bemcentinib
12 Jul 2021 //
PRNEWSWIRE
BerGenBio Presents Encouraging Combined Data for Bemcentinib
12 Jul 2021 //
PRNEWSWIRE
BerGenBio Presents Encouraging Combined Data for Bemcentinib
12 Jul 2021 //
PRNEWSWIRE
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study
11 Jun 2021 //
PRNEWSWIRE
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study
11 Jun 2021 //
PRNEWSWIRE
BerGenBio Receives Fast Track Designation For Bemcentinib / Anti-PD-(L)1
08 Jun 2021 //
PRNEWSWIRE
BerGenBio announces positive data from phase II trial of bemcentinib
18 May 2021 //
PHARMABIZ
US to donate 20M more vaccines overseas; BerGenBio hopes for the best
18 May 2021 //
ENDPTS
BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib
18 May 2021 //
PRNEWSWIRE
BerGenBio Announces Update From Investigational Ph II Trials Bemcentinib
19 Apr 2021 //
PRNEWSWIRE
BERGENBIO COMPLETES ENROLMENT INTO LATEST COHORT OF PHASE II BEMCENTINIB
12 Mar 2021 //
CISION
BerGenBio Presents Updated Clinical Data From Two Ph II Of Bemcentinib
07 Dec 2020 //
PRNEWSWIRE
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC
11 Nov 2020 //
PRNEWSWIRE
BerGenBio Presents Ph II Bemcentinib Combination Study in NSCLC at Annual SITC
11 Nov 2020 //
PRNEWSWIRE
BerGenBio to Present at Digital Novel Coronavirus Investment Forum
07 Jul 2020 //
PRNEWSWIRE
BerGenBio Announces +ve Interim Clinical & Phase II Trial of Bemcentinib
25 Jun 2020 //
PRNEWSWIRE
BerGenBio Announces Change to Presentation Time at Next Gen Immuno-Oncology
24 Jun 2020 //
PRNEWSWIRE
BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib
14 Jun 2020 //
PRNEWSWIRE
UK hospitals to trial five new drugs in search for coronavirus treatment
02 Jun 2020 //
THEGUARDIAN
Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial
01 Jun 2020 //
PRNEWSWIRE
BerGenBio Raises Nok500m (€45.4m) via an Over Subscribed Private Placement
05 May 2020 //
PR NEWSWIRE
BerGenBio`s Bemcentinib Selected to be Fast-tracked as Treatment for COVID-19
28 Apr 2020 //
PR NEWSWIRE
BerGenBio`s Bemcentinib Selected to Be Fast-tracked As for COVID-19
28 Apr 2020 //
PR NEWSWIRE
BerGenBio Meets Endpoint For First Stage Of Phase II Trial With Bemcentinib
15 Jan 2020 //
PR NEWSWIRE
Piramal Pharma Solutions partners with Norway-based BerGenBio
10 Dec 2019 //
MONEYCONTROL
BerGenBio Presents Preliminary Clinical Data From Ph II Combo Trial Bemcentinib
09 Dec 2019 //
PR NEWSWIRE
Piramal Pharma Solutions partners with BerGenBio to develop blood cancer drug
03 Dec 2019 //
MONEY CONTROL
Bemcentinib, Keytruda combo hits endpoints in mid-stage NSCLC trial
08 Nov 2019 //
PHARMATIMES
BerGenBio to Present Clinical Data From PhII Combination Trial of Bemcentinib
07 Nov 2019 //
PR NEWSWIRE
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
22 Oct 2019 //
PR NEWSWIRE
Regeneron, ArQule track progress on response rates
17 Jun 2019 //
ENDPTS
BerGenBio posts updated data on trial of elderly AML patients
17 Jun 2019 //
FIERCE BIOTECH
BerGenBio to Present NSCLC and AML Clinical Data From Ph II Devp Programme
23 Apr 2019 //
PR NEWSWIRE
